Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

The stock's fall snapped a three-day winning streak.

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing ...

Morgan Stanley analyst Terence Flynn notes that Pfizer (PFE) announced that after a review of the totality of the data for its pipeline oral ...

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported ...

This result demonstrates the strength of Pfizer's core business. With limited patent losses and fewer older drugs following the divestiture of its off-patent division Upjohn (now part of Viatris ...